171 related articles for article (PubMed ID: 24050512)
1. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Chung KH; Lee DH; Jin E; Cho Y; Seo JY; Kim N; Jeong SH; Kim JW; Hwang JH; Shin CM
Gut Liver; 2014 Nov; 8(6):605-11. PubMed ID: 25368747
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
Bago J; Pevec B; Tomić M; Marusić M; Bakula V; Bago P
Wien Klin Wochenschr; 2009; 121(1-2):47-52. PubMed ID: 19263014
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
Helicobacter; 2006 Feb; 11(1):46-51. PubMed ID: 16423089
[TBL] [Abstract][Full Text] [Related]
5. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
Kang JM; Kim N; Lee DH; Park YS; Kim YR; Kim JS; Jung HC; Song IS
Helicobacter; 2007 Dec; 12(6):623-8. PubMed ID: 18001404
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Kwon YH; Kim N; Lee JY; Choi YJ; Yoon K; Nam RH; Suh JH; Lee JW; Lee DH
Scand J Gastroenterol; 2016 Mar; 51(3):270-6. PubMed ID: 26452405
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Kiliç ZM; Köksal AS; Cakal B; Nadir I; Ozin YO; Kuran S; Sahin B
Dig Dis Sci; 2008 Dec; 53(12):3133-7. PubMed ID: 18465244
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection.
Miehlke S; Krasz S; Schneider-Brachert W; Kuhlisch E; Berning M; Madisch A; Laass MW; Neumeyer M; Jebens C; Zekorn C; Knoth H; Vieth M; Stolte M; Lehn N; Morgner A
Helicobacter; 2011 Dec; 16(6):420-6. PubMed ID: 22059392
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Kadayifci A; Uygun A; Polat Z; Kantarcioğlu M; Kılcıler G; Başer O; Ozcan A; Emer O
Turk J Gastroenterol; 2012 Feb; 23(1):8-13. PubMed ID: 22505373
[TBL] [Abstract][Full Text] [Related]
10. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Wang Z; Wu S
Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
[TBL] [Abstract][Full Text] [Related]
11. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.
Liu KS; Hung IF; Seto WK; Tong T; Hsu AS; Lam FY; But DY; Wong SY; Leung WK
Gut; 2014 Sep; 63(9):1410-5. PubMed ID: 24295850
[TBL] [Abstract][Full Text] [Related]
12. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.
Laine L; Hunt R; El-Zimaity H; Nguyen B; Osato M; Spénard J
Am J Gastroenterol; 2003 Mar; 98(3):562-7. PubMed ID: 12650788
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
[TBL] [Abstract][Full Text] [Related]
14. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
[TBL] [Abstract][Full Text] [Related]
15. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Boixeda D; Bermejo F; Martín-De-Argila C; López-Sanromán A; Defarges V; Hernández-Ranz F; Milicua JM; García-Plaza A
Aliment Pharmacol Ther; 2002 Aug; 16(8):1457-60. PubMed ID: 12182745
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN; Hahm JS; Kim HJ
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
[TBL] [Abstract][Full Text] [Related]
18. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.
Ciccaglione AF; Cellini L; Grossi L; Marzio L
World J Gastroenterol; 2012 Aug; 18(32):4386-90. PubMed ID: 22969203
[TBL] [Abstract][Full Text] [Related]
19. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
20. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
Miehlke S; Schneider-Brachert W; Kirsch C; Morgner A; Madisch A; Kuhlisch E; Haferland C; Bästlein E; Jebens C; Zekorn C; Knoth H; Stolte M; Lehn N
Helicobacter; 2008 Feb; 13(1):69-74. PubMed ID: 18205669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
